Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit
01:16am, Thursday, 18'th Sep 2025
SAN DIEGO , Sept. 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NA
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Cytokinet
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate p
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
04:02pm, Tuesday, 16'th Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and
Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
02:04pm, Tuesday, 09'th Sep 2025
Cytokinetics, Incorporated (NASDAQ:CYTK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Fady Malik - Executive Vice President of Research
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
03:32pm, Wednesday, 03'rd Sep 2025
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
11:06am, Wednesday, 03'rd Sep 2025
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript
05:43pm, Tuesday, 02'nd Sep 2025
Cytokinetics, Incorporated (NASDAQ:CYTK ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executiv
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential
02:07pm, Tuesday, 02'nd Sep 2025
MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is signif
Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript
12:23pm, Tuesday, 02'nd Sep 2025
Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of
Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.
11:09am, Tuesday, 02'nd Sep 2025
Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
12:10pm, Sunday, 31'st Aug 2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology
Cytokinetics' drug more effective for heart disease symptoms than standard-of-care
03:27am, Saturday, 30'th Aug 2025
Cytokinetics' experimental drug improved symptoms such as shortness of breath and chest pain better than a standard-of-care treatment in patients with a type of heart condition, detailed late-stage st
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
03:18am, Saturday, 30'th Aug 2025
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and
